key: cord-0067716-xd6gbg3h
authors: Wang, Xiaochen; Pan, Ziwei; Wang, Jue; Wang, Hongkun; Fan, Hangping; Gong, Tingyu; Sun, Qiming; Feng, Ye; Liang, Ping
title: Characterization of the molecular mechanisms underlying azithromycin‐induced cardiotoxicity using human‐induced pluripotent stem cell‐derived cardiomyocytes
date: 2021-09-16
journal: Clin Transl Med
DOI: 10.1002/ctm2.549
sha: caa5971ede98d5f6a787666d0a0e243f32df5a1a
doc_id: 67716
cord_uid: xd6gbg3h

nan

Starting from 3 μM, acute AZM treatment caused significantly increased beating rate and shortened FPD (Figure 1F , Table S1 ). We observed no arrhythmic activity even at the maximal tested concentration of AZM. Consistent with previous studies, 5, 6 we observed that 100 μM AZM caused approximately 20% inhibition of human ether-àgo-go-related gene (hERG) currents, indicating a minimal effect on hERG ( Figure S6 ). Ca 2+ currents isolated from 10 and 30 μM AZM-treated iPSC-CMs were significantly reduced, and steady-state activation (SSA) curve in 30 μM AZM-treated iPSC-CMs was significantly rightshifted ( Figure 1G -L, Table S2 ). Moreover, acutely treated with 30 μM AZM, Na + current density was significantly decreased, and steady-state inactivation (SSI) was significantly left-shifted ( Figure 1M -R, Table S2 ). No significant change was observed in K + current recordings ( Figure S7 ).

Electrophysiological effects of chronic AZM in iPSC-CMs were also assessed. DMSO caused slight changes of FPs on day 1, which were diminished along the treatment and recovered to baseline on day 5 (Figure 2A ,B, Table S3 ). Consistent with the observations of acute AZM treatment, dramatic changes of FPs were seen starting on day 1, resulting in accelerated beating rate and FPD shortening, which stayed constant from day 2 to day 5 postinduction (Figure 2C,D, Table S3 ). No arrhythmic activities were detected throughout 5-day recordings. Ca 2+ currents were largely reduced in AZM-treated iPSC-CMs while Na + and K + currents remained unchanged ( Figure 2E -P, Figure S8 , Table  S4 ).

We next sought to determine whether AZM can induce cell death and morphological changes. Starting from 10 μM, we observed cytotoxic effects in AZM-treated iPSC-CMs in a concentration-and time-dependent manner ( Figure 3A, FigureS9) . Significantly reduced cell viability was noted in three iPSC-CM lines starting from 30 μM AZM ( Figure 3B ). We thus selected the 5-day 30 μM AZM treatment plan for downstream assays. Importantly, we observed severe morphological phenotypes in AZMtreated iPSC-CMs, including formation of intracellular vacuoles and sarcomeric damage ( Figure 3C ,D, Figures S10-S12). Reactive oxygen species (ROS) was significantly increased in AZM-treated iPSC-CMs, whereas anti-oxidant markedly reversed the ROS amount elevation and ameliorated AZM-induced cell viability reduction ( Figure S13 ).

To further elucidate the underlying mechanisms, we performed RNA sequencing of control and AZM-treated iPSC-CMs, which demonstrated that differentially expressing genes (DEGs) were enriched in lysosome pathway ( Figures S14-S15 ). To test if AZM-induced cytotoxicity correlates with lysosomes, we performed live-cell confocal microscopy using pH-sensitive LysoTracker as a specific dye for lysosomes. 7, 8 Similar with chloroquine (CQ), AZM caused markedly enlarged, dilatate, and accumulated lysosomes ( Figure 3E ). Expression of lysosomal associated membrane protein 2 (LAMP2), a specific marker for lysosomes, was significantly enhanced in AZM-treated iPSC-CMs ( Figure 3F ,G), whereas cathespin D expression was unchanged ( Figure S16 ). Transmission electron microscope exhibited greatly increased number of lysosomes and autophagosomes in AZM-treated iPSC-CMs ( Figure 3H ). Given that the lysosome is a key factor in autophagy, we next investigated if AZM-induced lysosomal changes may affect autophagy flux. 8 We observed a high proportion of red puncta in untreated cells, indicating the basal state of the autolysosomes. In contrast, the proportion of red puncta was significantly lower in AZM-or CQ-treated iPSC-CMs ( Figure 3I ,J).

Moving forward, we sought to determine how AZM affects autophagy. AZM-treated iPSC-CMs demonstrated a significantly increased protein expression of microtubule associated protein 1 light chain (LC3)-II/LC3-I and p62, pointing to suppressed late-stage autophagy ( Figure 3K -P). Moreover, iPSC-CMs were treated with bafilomycin A 1 (BafA 1 ) to block fusion of autophagosomes with lysosomes. 9 BafA 1 did not affect AZM-induced p62 and LC3-II/LC3-I upregulation, further indicating that AZM causes impaired autophagy flux and autophagosome maturation ( Figure 3Q -S, Figure S17 ). However, expression of beclin 1 remained unchanged ( Figure S18 ).

We next assessed whether intervention of autophagy may rescue AZM-induced cytotoxic phenotypes in iPSC-CMs. 10 Induction of autophagy by specific mTOR inhibitor Torin showed no rescuing effects ( Figure 4A -C, G, Figure S19 -S20). In contrast, inhibition of early-stage autophagy by ULK1 inhibitor MRT68921 significantly restored AZM-induced p62 and LC3-II/LC3-I upregulation, and effectively rescued the reduced cell viability phenotype, although failed to rescue vacuole formation and enhanced LAMP2 expression ( Figure 4D -F, H-M, Figure  S21 -S22). Interestingly, we found that removal of AZMcontaining medium significantly rescued AZM-induced cytotoxic phenotypes, exhibiting not only restored cell viability, but also suppressed vacuole formation and rescued lysosomes ( Figure 4N ,O).

In conclusion, low-concentration AZM is electrophysiologically and morphologically noncardiotoxic, whereas high-concentration AZM may cause dramatic QT shorten-Prominent prolongation of FPD and FPDc was observed in response to acute treatment of MXF in a concentration-dependent manner. BP was significantly increased at 30 and 100 μM, suggesting a slower effect on beating rate induced by MXF. Note that 30 and 100 μM MXF had largely decreased effect on FPA. Mycoytes were derived from three different iPSC lines. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. (E) Representative FP tracings recorded from iPSC-CMs with acute treatment of 0, 1, 3, 10, and 30 μM AZM, respectively. (F) Acute effects of AZM on BP, FPD, FPDc, and FPA. Beating rate, reflected by BP, was significantly increased started at the concentration of 3 μM AZM. Starting from 3 μM, acute treatment of AZM gave rise to markedly shortened FPD and FPDc. The FPA was significantly decreased by 10 and 30 μM AZM treatment. Mycoytes were derived from three different iPSC lines. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. (G) Representative Ca 2+ current tracings isolated from control iPSC-CMs and iPSC-CMs with acute treatment of 30 μM AZM. Myocytes were derived from iPSC #3. (H) Comparison of Ca 2+ current-voltage relationship curve (IV curve) between control iPSC-CMs and iPSC-CMs with acute treatment of 1, 10, and 30 μM AZM. (I) Bar graph to compare peak Ca 2+ current density at 0 mV between different groups in H. n = 8-13. We observed concentration-dependent inhibition of Ca 2+ currents in AZM-treated iPSC-CMs, and significant changes were achieved at 10 and 30 μM. *** p < 0.001 and **** p < 0.0001. (J) Comparison of steady-state activation (SSA) and steady-state inactivation (SSI) of Ca 2+ current between control iPSC-CMs and iPSC-CMs with acute treatment of 1, 10, and 30 μM AZM. (K and L) Bar graphs to compare V 1/2 of SSA and SSI of Ca 2+ current between different groups in J. SSA, n = 7-12; SSI, n = 8-9. SSA curve of Ca 2+ currents in 30 μM AZM-treated iPSC-CMs was significantly right-shifted as compared to controls, whereas SSI curves of Ca 2+ currents stayed unchanged between control and AZM-treated iPSC-CMs. * p < 0.05. (M) Representative Na + current tracings isolated from control iPSC-CMs and iPSC-CMs with acute treatment of 30 μM AZM. (N) Comparison of Na + IV curve between control iPSC-CMs and iPSC-CMs with acute treatment of 10 and 30 μM AZM. Myocytes were derived from iPSC #3. (O) Bar graph to compare peak Na + current density at −30 mV between different groups in N. n = 5-11. Slight reduction of Na + currents was noted by acute treatment of 10 μM AZM, and this change turned to be statistically significant upon 30 μM AZM treatment. *** p < 0.001. (P) Comparison of SSA and SSI of Na + current between control iPSC-CMs and iPSC-CMs with acute treatment of 10 and 30 μM AZM. (Q and R) Bar graphs to compare V 1/2 of SSA and SSI of Na + current between different groups in P. SSA, n = 5-10; SSI, n = 5-11. SSA curves of Na + currents were comparable between control and AZM-treated iPSC-CMs. However, SSI curve of Na + currents in 30 μM AZM-treated iPSC-CMs was significantly left-shifted. * p < 0.05 ing, cardiomyocyte death, and structural damage but has no proarrhythmic risk in healthy control populations. Our findings suggest that AZM can be prescribed when warranted, but attention should be paid to high-risk patients with preexisting comorbidities ( Figure 4P ).

The authors declare that there is no conflict of interest.

We would like to thank the core facility of Zhejiang University Institute of Translational Medicine for assistance with flow cytometry and confocal microscopy experiments. This work was supported by National Key R&D Program of China 2017YFA0103700 (P.L.), the National Natural Science Foundation of China (No. 81922006, 81870175) (P.L.), and the Natural Science Foundation of Zhejiang Province (No. LD21H020001) (P.L.). P.L. would like to thank Natalie Liang and Michael Liang for their encouragement and consistent support.

P.L., Y.F. and Q.S. designed and supervised the study. X.W., Z.P., J.W., H.W., H.F., T.G. and Y.F. performed the experiments and analyzed data. Z.P. and P.L. wrote the manuscript.

The data that support the findings of the study are available from the corresponding author upon reasonable request.

Xiaochen Wang 1,2,# Ziwei Pan 1,2,# Jue Wang 1,2 Hongkun Wang 1, 2 Hangping Fan 1,2 Tingyu Gong 1,2 Qiming Sun 4 Ye Feng 2,3 Ping Liang 1,2 O R C I D Ping Liang https://orcid.org/0000-0001-6806-3735

*** p < 0.001, and **** p < 0.0001. (I) Representative confocal images of brightfield and LysoTracker staining in control iPSC-CMs, AZM-treated iPSC-CMs, ULK1i-treated iPSC-CMs, or iPSC-CMs treated with AZM and ULK1i. Myocytes were derived from iPSC #1. Scale bar = 20 μm. (J) Western blot analysis of LAMP2, p62 and LC3-II/LC3-I expression in control and AZM-treated myocytes derived from iPSC #1 with or without ULK1i. (K-M) Bar graphs to compare LAMP2, p62 and LC3-II/LC3-I expression between different groups in J

Representative confocal images of brightfield and LysoTracker staining in control iPSC-CMs, AZM-treated iPSC-CMs, AZM-treated iPSC-CMs with 2-day AZM withdrawal. Myocytes were derived from iPSC #1. Scale bar = 20 μm. Removal of AZM-containing medium for 2 days significantly rescued AZM-induced cytotoxic phenotypes in iPSC-CMs. (P) Proposed work model of AZM-induced cardiotoxicity. Electrophysiologically, high-concentration AZM causes accelerated beating rate and dramatically shortened QTc in the absence of proarrhythmic risk in healthy control populations by acutely suppressing Na + and Ca 2+ channels, or chronically suppressing Ca 2+ channel. Morphologically, high-concentration AZM interferes with lysosomal activity to impair autophagy flux and autophagosome maturation. The futile and excessive autophagosome formation and accumulation confers vacuole formation, sarcomeric damage, and cardiomyocyte death. Inhibition of early-stage autophagy to alleviate the burden of autophagosome accumulation by ULK1i may partially rescue the deleterious phenotypes 1

Use of azithromycin and death from cardiovascular causes

Azithromycin causes a novel proarrhythmic syndrome

Comprehensive translational assessment of human-induced pluripotent stem cell derived cardiomyocytes for evaluating drug-induced arrhythmias

Cardiotoxic potential of hydroxychloroquine, chloroquine and azithromycin in adult human primary cardiomyocytes

Covid-19 drugs chloroquine and hydroxychloroquine, but not azithromycin and remdesivir, block herg potassium channels

Lysosomotropic agents including azithromycin, chloroquine and hydroxychloroquine activate the integrated stress response

Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion

Guidelines for the use and interpretation of assays for monitoring autophagy

Accumulation of autophagosomes confers cytotoxicity